145 related articles for article (PubMed ID: 28118654)
1. Comparison chart of SGLT2 inhibitors.
Med Lett Drugs Ther; 2017 Jan; 59(1513):e26. PubMed ID: 28118654
[No Abstract] [Full Text] [Related]
2. SGLT2 inhibitors: new reports.
Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
[TBL] [Abstract][Full Text] [Related]
3. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Bloomgarden ZT
J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
[No Abstract] [Full Text] [Related]
5. Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes-2015 Interim Update.
; Harper W; Clement M; Goldenberg R; Hanna A; Main A; Retnakaran R; Sherifali D; Woo V; Yale JF; Cheng AY;
Can J Diabetes; 2015 Aug; 39(4):250-2. PubMed ID: 26233723
[No Abstract] [Full Text] [Related]
6. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
Messana JA; Schwartz SS; Townsend RR
Vasc Health Risk Manag; 2017; 13():43-54. PubMed ID: 28255241
[TBL] [Abstract][Full Text] [Related]
7. European Association for the Study of Diabetes 51st Annual Meeting.
Gao HX; Regier EE; Close KL
J Diabetes; 2016 Mar; 8(2):177-80. PubMed ID: 26606912
[No Abstract] [Full Text] [Related]
8. Canagliflozin: a new option for managing diabetes.
Livingston M; Clements JN
JAAPA; 2014 Sep; 27(9):47-50. PubMed ID: 25148443
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
Misra M
J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
[TBL] [Abstract][Full Text] [Related]
11. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
Vallon V; Thomson SC
Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
[No Abstract] [Full Text] [Related]
12. [Pharmacological and clinical profile of a novel SGLT2 inhibitor canagliflozin hydrate (CANAGLU®)].
Kuriyama C; Ueta K; Arakawa K
Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):332-41. PubMed ID: 26657125
[No Abstract] [Full Text] [Related]
13. Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol.
Fortuna D; McCloskey LJ; Stickle DF
Clin Chim Acta; 2016 Jan; 452():138-41. PubMed ID: 26569347
[TBL] [Abstract][Full Text] [Related]
14. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
15. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
Basile JN
J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
[TBL] [Abstract][Full Text] [Related]
16. [Mode of SGLT inhibition by an SGLT2 inhibitor, canagliflozin and implication in renal and small intestinal effects].
Kuriyama C
Nihon Yakurigaku Zasshi; 2016; 148(5):245-252. PubMed ID: 27803437
[No Abstract] [Full Text] [Related]
17. SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus.
Deshmukh AB; Patel MC; Mishra B
Ren Fail; 2013; 35(4):566-72. PubMed ID: 23438184
[TBL] [Abstract][Full Text] [Related]
18. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
Davies MJ; Trujillo A; Vijapurkar U; Damaraju CV; Meininger G
Diabetes Obes Metab; 2015 Apr; 17(4):426-9. PubMed ID: 25600248
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose transporter 2 inhibitors in type 2 diabetes mellitus: navigating between Scylla and Charybdis.
Machado UF; Corrêa-Giannella ML
Expert Opin Emerg Drugs; 2014 Mar; 19(1):5-9. PubMed ID: 24397354
[TBL] [Abstract][Full Text] [Related]
20. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
